|
|
Article: HemoBioTech Engages CRO to Facilitate Clinical Study in India of Its Human Blood Substitute, HemoTech.
- Article from:
- PR Newswire
- Article date:
- June 21, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
'HemoBioTech is developing what we hope will be the world's first viable substitute for human blood, licensed on an exclusive basis from Texas Tech University Health Sciences Center.'
Lt. General Bernhard Mittemeyer, M.D. Interim President, Texas Tech University Health Sciences Center; Former U.S. Army Surgeon General; HemoBioTech Director
DALLAS, June 21 /PRNewswire-FirstCall/ -- HemoBioTech (BULLETIN BOARD: HMBT) announced today that it has engaged Paragon Biomedical (http://www.parabio.com/) to provide regulatory and clinical services in India related to the Company's proposed human blood substitute, HemoTech. Paragon will submit preclinical data ...